18F-FDG PET Metabolic Parameters and MRI Perfusion and Diffusion Parameters in Hepatocellular Carcinoma: A Preliminary Study

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Ahn, Sung Jun ^a   Park, Mi Suk ^a   Kim, Kyung Ah ^a   Park, Jun Yong ^a   Kim, InSeong ^b   Kang, Won Joon ^a   Lee, Seung Koo ^a   Kim, Myeong Jin ^a  

^a Yonsei University College of Medicine   (South Korea)

^b SIEMENS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; MALE; MEDICAL PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL PHENOMENA; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; STANDARD UPTAKE VALUE; TUMOR CELLULARITY; TUMOR METABOLISM; TUMOR VASCULARIZATION; VOLUME TRANSFER CONSTANT; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; SCINTIGRAPHY; VASCULARIZATION; LIVER TUMOR; METHODOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 84881115718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071571     Document Type: Article

References (22)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
3. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, et al. (2003) Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 228: 63-69.
4. Park MS, Klotz E, Kim MJ, Song SY, Park SW, et al. (2009) Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 250: 110-117.
5. Lee JH, Park JY, Kim do Y, Ahn SH, Han KH, et al. (2011) Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 31: 1144-1149.
6. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, et al. (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27: 3027-3035.
7. Schraml C, Schwenzer NF, Martirosian P, Bitzer M, Lauer U, et al. (2009) Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 193: W301-307.
8. Jarnagin WR, Schwartz LH, Gultekin DH, Gonen M, Haviland D, et al. (2009) Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 20: 1589-1595.
9. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, et al. (2011) Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 55: 858-865.
10. Llovet JM, Bru C, Bruix J, (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
11. Crum WR, Hartkens T, Hill DL, (2004) Non-rigid image registration: theory and practice. Br J Radiol 77 Spec No 2: S140-153.
12. Sahani DV, Holalkere NS, Mueller PR, Zhu AX, (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 243: 736-743.
13. Asayama Y, Yoshimitsu K, Nishihara Y, Irie H, Aishima S, et al. (2008) Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation. AJR Am J Roentgenol 190: W28-34.
14. Law M, Yang S, Wang H, Babb JS, Johnson G, et al. (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24: 1989-1998.
15. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, et al. (2010) The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 39: 799-800.
16. Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, et al. (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57: 575-581.
17. Crowley LV (2011) Essentials of human disease. Sudbury, Mass.: Jones and Bartlett Publishers. xxi, 553 p. p.
18. Mineura K, Yasuda T, Kowada M, Shishido F, Ogawa T, et al. (1986) Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurol Res 8: 164-168.
19. Patankar TF, Haroon HA, Mills SJ, Baleriaux D, Buckley DL, et al. (2005) Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 26: 2455-2465.
20. Zasadny KR, Tatsumi M, Wahl RL, (2003) FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30: 274-280.
21. Emblem KE, Nedregaard B, Nome T, Due-Tonnessen P, Hald JK, et al. (2008) Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 247: 808-817.
22. Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, et al. (2008) Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 29: 471-475.